October 28, 2011 — Accuray Inc. announced the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market the Dose Control System (DCS), a new performance-improving feature for its TomoTherapy system.
The TomoTherapy system introduced helical delivery to radiation therapy, providing precise application of dose to target structures while sparing healthy tissue. With the advent of the DCS, the system becomes the first dose servo-controlled helical delivery system (patent pending).
This approach provides even higher precision and dose stability throughout complex rotational treatments. Static delivery provided by the TomoDirect option also benefits from a more stable and consistent dose rate at every gantry angle.
The new DCS feature provides these gains by automatically adjusting controls previously handled through a manual process. This means small variations in dose rate are immediately corrected by the system, resulting in fewer interruptions. The DCS application also ensures a more stable output over longer duration treatments, such as total marrow and total body irradiation.
With the FDA 510(k) clearance, the DCS application is now available for purchase in the United States.
For more information: www.accuray.com
August 09, 2024 
